Aveanna Healthcare (NASDAQ:AVAH) Insider Edwin Reisz Sells 42,057 Shares

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) insider Edwin Reisz sold 42,057 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $7.65, for a total transaction of $321,736.05. Following the transaction, the insider directly owned 1,567,043 shares of the company’s stock, valued at $11,987,878.95. This represents a 2.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Aveanna Healthcare Stock Down 1.4%

Shares of AVAH stock traded down $0.10 during trading hours on Friday, hitting $7.32. 153,574 shares of the company’s stock traded hands, compared to its average volume of 1,228,412. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 140.39. The stock’s fifty day simple moving average is $8.48 and its two-hundred day simple moving average is $8.44. Aveanna Healthcare Holdings Inc. has a 12-month low of $3.67 and a 12-month high of $10.32. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of 20.40 and a beta of 2.06.

Hedge Funds Weigh In On Aveanna Healthcare

Hedge funds have recently bought and sold shares of the business. Quantbot Technologies LP bought a new position in Aveanna Healthcare during the 2nd quarter valued at about $43,000. MQS Management LLC bought a new stake in shares of Aveanna Healthcare in the second quarter worth approximately $59,000. Belvedere Trading LLC bought a new stake in shares of Aveanna Healthcare in the second quarter worth approximately $62,000. Oxford Asset Management LLP bought a new position in Aveanna Healthcare during the second quarter valued at approximately $64,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Aveanna Healthcare during the second quarter valued at approximately $68,000. Hedge funds and other institutional investors own 87.96% of the company’s stock.

Aveanna Healthcare News Summary

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Insiders still retain meaningful stakes — despite the sales, CEO Jeff Shaner, CFO Matthew Buckhalter and other insiders continue to hold multi‑million‑dollar positions, which may signal ongoing alignment with shareholders. SEC Filing
• Neutral Sentiment: Reported short interest data shows zero shares (likely a data/reporting anomaly), so there’s no clear short‑selling pressure indicated by that statistic. Short Interest
• Neutral Sentiment: Today’s trading volume was well below the recent average, which can amplify price moves when large block trades or news hit the tape. (Context from recent price/volume data.)
• Negative Sentiment: Large, concentrated insider selling across Feb. 17–19: CEO Jeff Shaner sold roughly 461,900 shares across the three days (totaling about $3.4M), other executives including an additional director and senior officers sold substantial blocks, and cumulative insider disposals during the period totalled in the high hundreds of thousands of shares — a clear negative catalyst that likely pushed the stock down. See CEO filings. CEO Sales SEC Filing
• Negative Sentiment: Multiple additional executive/director sales (CFO, CAO, and other insiders sold across the same dates), including material dispositions by Edwin C. Reisz and Patrick A. Cunningham, reinforcing a market interpretation that insiders are taking profits or reducing exposure at current levels. Example filings here. Other Insider Filings
• Negative Sentiment: Coverage/analysis noting the drop: independent commentary flagged the same insider selling as the primary reason for a recent ~5.7% pullback, reinforcing market attention on the sales. AAII Article

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on AVAH. UBS Group increased their target price on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “neutral” rating in a research note on Thursday, January 15th. Barclays increased their price objective on shares of Aveanna Healthcare from $9.00 to $11.00 and gave the company an “overweight” rating in a research report on Friday, January 16th. Zacks Research cut shares of Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. Truist Financial upped their target price on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “hold” rating in a research note on Friday, November 7th. Finally, William Blair assumed coverage on shares of Aveanna Healthcare in a report on Monday, December 8th. They set an “outperform” rating on the stock. Five investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $11.06.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.